Sunrise to Emphasize How to Increase Procedure Volume at the ASCRS

Apr 24, 2001, 01:00 ET from Sunrise Technologies International, Inc.

    FREMONT, Calif., April 24 /PRNewswire Interactive Press Release/ --
 Sunrise Technologies International, Inc. (Nasdaq:   SNRS), announced today
 previewed its activities at the American Society of Cataract and Refractive
 Surgery (ASCRS) meeting in San Diego April 27-May 1, 2001. The Company has
 scheduled 14 separate presentations at its booth (#1431) that will educate
 refractive surgeons on the SUNRISE LTK(TM) procedure and marketing to the
 hyperopic population.
     "There is a large opportunity for treatment of hyperopia. The hyperopic
 patient is a little older than the traditional myopic patient and is motivated
 to have the surgery for different reasons. Some of our customers have already
 capitalized on those differences. At our ASCRS booth, surgeons performing the
 Sunrise LTK procedure from around the country will be sharing some of these
 remarkable success stories including treatments on themselves," said
 C. Russell Trenary III, Sunrise Chairman and Chief Executive Officer.
     Among the presenters will be noted Chicago refractive surgeon
 Dr. Randy Epstein, who will review his own LTK treatment that occurred earlier
 this month:
 
     "Non-Contact LTK:  A Refractive Surgeon's Personal Experience," presented
 by Randy Epstein, MD, Chicago Cornea Consultants. (10 a.m. Sunday, April 29)
 
     Sunrise will also emphasize marketing to the hyperopic patients by
 reviewing services the Company has developed in its QuickStart Program:
 
     "Free & Easy Service for Immediate Success with LTK Using the Sunrise
 QuickStart Program," presented by Kerrick Securda, Senior Director World Wide
 Markerting for Sunrise. (4 p.m. Saturday April 28. Repeated 4 p.m.
 Sunday, April 29 & 2 p.m. Monday, April 30)
 
     Among the other talks scheduled are:
 
     "Why I Have a HYPERION(TM) LTK System Next to My Excimer Laser," presented
 by Lanny Hale, MD, Hale Vision Correction Center. Dr. Hale owns laser centers
 in Arizona and Wisconsin and has the HYPERION(TM) LTK System at both sites.
 (11 a.m. Saturday April 28. Repeated 10 a.m. Monday, April 30)
 
     "What I Have Learned In My First 6 Months: Myths & Facts on Treating
 Hyperopia and the HYPERION LTK System," presented by Mark Milner MD,
 Co-Medical Director-Precision Laser Vision Centers, in Hamden, Connecticut.
 (12 p.m. Saturday, April 28)
 
     "Why I View My HYPERION LTK System as a Signature Product," presented by
 Howard Straub, DO, Colorado Eye Institute & Laser Center in Denver. (11 a.m.
 Sunday, April 29)
 
     All of the scheduled booth talks and their times are listed on the Company
 website at www.sunrise-tech.com.
     Thirteen surgeons performing the SUNRISE LTK procedure will be presenting
 at the conference. The bulk of those presentations will be on Monday and
 Tuesday. The schedule of those papers and programs are also presented on the
 Company website.
     "We are very excited about the ASCRS this year. It is the largest
 refractive surgery meeting in the world. It is the first ASCRS meeting at
 which we have an approved product. One of our key tasks now is helping the
 surgeons drive hyperopic volume into their practices. We believe we are well
 prepared for this opportunity," added Trenary.
     The U.S. Food and Drug Administration approved the Company's HYPERION(TM)
 LTK System on June 30, 2000 for the temporary reduction of hyperopia in
 patients with +0.75 to +2.50 diopters of MRSE with less than or equal to
 +/- 0.75 diopters of astigmatism, who are 40 years of age or older with
 documented stability of refraction for the prior 6 months, as demonstrated by
 a change of less than or equal to 0.50D in spherical and cylindrical
 components of the manifest refraction. The magnitude of correction with this
 treatment diminishes over time, with some patients retaining some or all of
 their refractive correction. The new labeling says that, based upon existing
 information for the clinical parameters used in the clinical trial, the
 Company's model for the average longevity for the procedure indicates that
 some of the effect lasts 10 years and beyond. Age related drift towards
 hyperopia contributes to the loss of effect after the initial two years.
     Sunrise Technologies International, Inc. is a refractive surgery company
 based in Fremont, California, that has developed holmium:YAG laser-based
 systems that utilize a patented process for shrinking collagen developed by
 Dr. Bruce Sand (the "Sand Process") in correcting ophthalmic refractive
 conditions.
     Except for historical information, this news release contains certain
 forward-looking statements that involve risk and uncertainties, which may
 cause actual results to differ materially from the statements made including
 market potential, regulatory clearances, business growth, and other risks
 listed from time to time in the Company's Securities and Exchange Commission
 (SEC) filings. These forward-looking statements represent the Company's
 judgment, as of the date of this release, and the Company disclaims any intent
 or obligation to update these forward-looking statements.
     Internet users can access Sunrise's World Wide Web site at
 http://www.sunrise-tech.com .
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X77614356
 
 

SOURCE Sunrise Technologies International, Inc.
    FREMONT, Calif., April 24 /PRNewswire Interactive Press Release/ --
 Sunrise Technologies International, Inc. (Nasdaq:   SNRS), announced today
 previewed its activities at the American Society of Cataract and Refractive
 Surgery (ASCRS) meeting in San Diego April 27-May 1, 2001. The Company has
 scheduled 14 separate presentations at its booth (#1431) that will educate
 refractive surgeons on the SUNRISE LTK(TM) procedure and marketing to the
 hyperopic population.
     "There is a large opportunity for treatment of hyperopia. The hyperopic
 patient is a little older than the traditional myopic patient and is motivated
 to have the surgery for different reasons. Some of our customers have already
 capitalized on those differences. At our ASCRS booth, surgeons performing the
 Sunrise LTK procedure from around the country will be sharing some of these
 remarkable success stories including treatments on themselves," said
 C. Russell Trenary III, Sunrise Chairman and Chief Executive Officer.
     Among the presenters will be noted Chicago refractive surgeon
 Dr. Randy Epstein, who will review his own LTK treatment that occurred earlier
 this month:
 
     "Non-Contact LTK:  A Refractive Surgeon's Personal Experience," presented
 by Randy Epstein, MD, Chicago Cornea Consultants. (10 a.m. Sunday, April 29)
 
     Sunrise will also emphasize marketing to the hyperopic patients by
 reviewing services the Company has developed in its QuickStart Program:
 
     "Free & Easy Service for Immediate Success with LTK Using the Sunrise
 QuickStart Program," presented by Kerrick Securda, Senior Director World Wide
 Markerting for Sunrise. (4 p.m. Saturday April 28. Repeated 4 p.m.
 Sunday, April 29 & 2 p.m. Monday, April 30)
 
     Among the other talks scheduled are:
 
     "Why I Have a HYPERION(TM) LTK System Next to My Excimer Laser," presented
 by Lanny Hale, MD, Hale Vision Correction Center. Dr. Hale owns laser centers
 in Arizona and Wisconsin and has the HYPERION(TM) LTK System at both sites.
 (11 a.m. Saturday April 28. Repeated 10 a.m. Monday, April 30)
 
     "What I Have Learned In My First 6 Months: Myths & Facts on Treating
 Hyperopia and the HYPERION LTK System," presented by Mark Milner MD,
 Co-Medical Director-Precision Laser Vision Centers, in Hamden, Connecticut.
 (12 p.m. Saturday, April 28)
 
     "Why I View My HYPERION LTK System as a Signature Product," presented by
 Howard Straub, DO, Colorado Eye Institute & Laser Center in Denver. (11 a.m.
 Sunday, April 29)
 
     All of the scheduled booth talks and their times are listed on the Company
 website at www.sunrise-tech.com.
     Thirteen surgeons performing the SUNRISE LTK procedure will be presenting
 at the conference. The bulk of those presentations will be on Monday and
 Tuesday. The schedule of those papers and programs are also presented on the
 Company website.
     "We are very excited about the ASCRS this year. It is the largest
 refractive surgery meeting in the world. It is the first ASCRS meeting at
 which we have an approved product. One of our key tasks now is helping the
 surgeons drive hyperopic volume into their practices. We believe we are well
 prepared for this opportunity," added Trenary.
     The U.S. Food and Drug Administration approved the Company's HYPERION(TM)
 LTK System on June 30, 2000 for the temporary reduction of hyperopia in
 patients with +0.75 to +2.50 diopters of MRSE with less than or equal to
 +/- 0.75 diopters of astigmatism, who are 40 years of age or older with
 documented stability of refraction for the prior 6 months, as demonstrated by
 a change of less than or equal to 0.50D in spherical and cylindrical
 components of the manifest refraction. The magnitude of correction with this
 treatment diminishes over time, with some patients retaining some or all of
 their refractive correction. The new labeling says that, based upon existing
 information for the clinical parameters used in the clinical trial, the
 Company's model for the average longevity for the procedure indicates that
 some of the effect lasts 10 years and beyond. Age related drift towards
 hyperopia contributes to the loss of effect after the initial two years.
     Sunrise Technologies International, Inc. is a refractive surgery company
 based in Fremont, California, that has developed holmium:YAG laser-based
 systems that utilize a patented process for shrinking collagen developed by
 Dr. Bruce Sand (the "Sand Process") in correcting ophthalmic refractive
 conditions.
     Except for historical information, this news release contains certain
 forward-looking statements that involve risk and uncertainties, which may
 cause actual results to differ materially from the statements made including
 market potential, regulatory clearances, business growth, and other risks
 listed from time to time in the Company's Securities and Exchange Commission
 (SEC) filings. These forward-looking statements represent the Company's
 judgment, as of the date of this release, and the Company disclaims any intent
 or obligation to update these forward-looking statements.
     Internet users can access Sunrise's World Wide Web site at
 http://www.sunrise-tech.com .
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X77614356
 
 SOURCE  Sunrise Technologies International, Inc.